Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Decrease in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 52,600 shares, a decrease of 22.0% from the October 15th total of 67,400 shares. Based on an average daily trading volume, of 47,600 shares, the short-interest ratio is currently 1.1 days.

Evaxion Biotech A/S Stock Performance

Shares of EVAX opened at $1.68 on Friday. The business has a 50-day simple moving average of $2.84 and a two-hundred day simple moving average of $3.10. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a 52 week low of $1.59 and a 52 week high of $13.61. The stock has a market cap of $9.37 million, a price-to-earnings ratio of -6.07 and a beta of -0.24.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. On average, analysts expect that Evaxion Biotech A/S will post -0.15 EPS for the current year.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC raised its holdings in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 392,000 shares of the company’s stock after acquiring an additional 25,000 shares during the quarter. Armistice Capital LLC owned approximately 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research note on Friday, November 1st.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.